Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan.

ESC Heart Failure
Toshihiro YamadaKenichi Tsujita

Abstract

The focus on wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is increasing because of novel treatment options. There is currently no report on a large number of Japanese patients with ATTRwt-CM. The study aimed to examine the characteristics and prognosis of ATTRwt-CM in Japan. Consecutive patients (78.5 ± 6.4 years old at diagnosis) with ATTRwt-CM diagnosed at Kumamoto University Hospital between December 2002 and December 2019 were retrospectively reviewed. Data, including demographic characteristics, co-morbidities, clinical manifestations at diagnosis, laboratory results, electrocardiographic and echocardiographic data, imaging and pathological findings, and treatment were obtained. Of 129 patients included in this study, 110 patients (85%) were male. The median period from initial symptom onset to diagnosis was 15.5 (2-75) months. Heart failure was the most common clinical manifestation leading to diagnosis (61%) and initial manifestations (49%). Of 106 patients, carpal tunnel syndrome was observed in 57 patients (54%), and the median period from initial symptom onset to diagnosis was 96 (48-120) months. Histopathological confirmation of transthyretin amyloid was achieved in 94 patients (73%), including 66 (51%)...Continue Reading

References

Jan 24, 2002·Neurology·Mauro MondelliMariano Giacchi
Sep 20, 2005·Journal of the American College of Cardiology·Enrica PeruginiClaudio Rapezzi
Feb 22, 2011·Human Pathology·Takanao SueyoshiHiroshi Mizuta
Apr 24, 2013·Journal of the American Heart Association·Jennifer H PinneyHelen J Lachmann
Apr 12, 2014·JACC. Heart Failure·Selma F MohammedMargaret M Redfield
Jul 30, 2015·European Journal of Heart Failure·Hiroaki ShimokawaYasuhiko Sakata
Aug 1, 2015·European Heart Journal·Esther González-LópezPablo Garcia-Pavia
Dec 4, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroaki KusakaHisao Ogawa
Feb 9, 2016·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Michitaka NakagawaShu-Ichi Ikeda
Jul 9, 2016·Journal of the American College of Cardiology·Mathew S MaurerUNKNOWN THAOS Investigators
Sep 3, 2016·Journal of the American College of Cardiology·Martha GroganAngela Dispenzieri
Sep 16, 2016·Scandinavian Journal of Work, Environment & Health·Yves RoquelaureBuisson Catherine
Mar 23, 2017·European Heart Journal·Esther González-LópezPablo Garcia-Pavia
Sep 5, 2017·ESC Heart Failure·Seiji TakashioKenichi Tsujita
Oct 20, 2017·European Heart Journal·Julian D GillmorePhilip N Hawkins
Nov 9, 2017·Journal of cardiology·Yasuhiro IzumiyaKenichi Tsujita
Nov 29, 2017·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Yoshiki SekijimaYukio Ando
Aug 28, 2018·The New England Journal of Medicine·Mathew S MaurerUNKNOWN ATTR-ACT Study Investigators
May 11, 2019·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·Seitaro OdaYasuyuki Yamashita
Jun 7, 2019·Journal of the American College of Cardiology·Frederick L RubergMathew S Maurer
Jul 6, 2019·Journal of the American College of Cardiology·Emil L FosbølFinn Gustafsson
Jul 16, 2019·JACC. Heart Failure·Ronald M WittelesPablo Garcia-Pavia

❮ Previous
Next ❯

Methods Mentioned

BETA
light microscopy
biopsy
biopsies
electrophoresis

Software Mentioned

ATTRwt
SPSS

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.